This article has been retracted by the publisher. The actin immunoblots in Figs. 2A, 2B , and 2C were reused in Figs. 3A, 3B, and 3C, respectively. Lanes 1, 3, and 5 of the PCMT immunoblot in Fig. 3B were reused in lanes 1, 3, and 5 of the PCMT immunoblot in Fig. 3C . The first lane of the PCMT immunoblot from Fig. 5 was reused in lane 1 of the PCMT immunoblot in Fig. 4 . The PARP immunoblot in Fig. 7A was inappropriately manipulated. The bands in Fig. 9A were duplicated. Fig. 9C was spliced. The BclxL immunoblot from Fig. 10A was duplicated in Fig. 10B . The Pro-Caspase 3 and Cleaved PARP immunoblots from Fig. 10A were inappropriately manipulated. The PCMT, BclxL, and Cleaved PARP immunoblots from Fig. 10B were inappropriately manipulated.
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